<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8</volume><submitter>Fang H</submitter><funding>Natural Science Foundation ofÂ Hunan Province</funding><pubmed_abstract>Schistosomiasis has been a fatal obstinate disease that threatens global human health, resulting in the granulomatous inflammation and liver fibrosis. &lt;b>Objective:&lt;/b>The aim of this study was to evaluate the therapeutic effects and mechanisms of hydroxyasiaticoside combined with praziquantel in the treatment of schistosomiasis-induced liver fibrosis. &lt;b>Methods:&lt;/b>Mice were randomly distributed into four experimental groups: normal control group, model group, praziquantel group, praziquantel + hydroxyasiaticoside group. Except for the normal control group, they were infected with &lt;i>Schistosomia cercariae&lt;/i> through the abdominal skin to induce liver fibrosis. In the intervention group, mice were administered with the respective drugs by gavage after 8 weeks of infection. At the end of</pubmed_abstract><journal>Frontiers in bioengineering and biotechnology</journal><pagination>613784</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7862569</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>&lt;i>In vivo&lt;/i> Therapeutic Effects and Mechanisms of Hydroxyasiaticoside Combined With Praziquantel in the Treatment of Schistosomiasis Induced Hepatic Fibrosis.</pubmed_title><pmcid>PMC7862569</pmcid><pubmed_authors>Fang H</pubmed_authors><pubmed_authors>Yu L</pubmed_authors><pubmed_authors>Guo W</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>You D</pubmed_authors><pubmed_authors>Peng N</pubmed_authors><pubmed_authors>Wang J</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>In vivo&lt;/i> Therapeutic Effects and Mechanisms of Hydroxyasiaticoside Combined With Praziquantel in the Treatment of Schistosomiasis Induced Hepatic Fibrosis.</name><description>Schistosomiasis has been a fatal obstinate disease that threatens global human health, resulting in the granulomatous inflammation and liver fibrosis. &lt;b>Objective:&lt;/b>The aim of this study was to evaluate the therapeutic effects and mechanisms of hydroxyasiaticoside combined with praziquantel in the treatment of schistosomiasis-induced liver fibrosis. &lt;b>Methods:&lt;/b>Mice were randomly distributed into four experimental groups: normal control group, model group, praziquantel group, praziquantel + hydroxyasiaticoside group. Except for the normal control group, they were infected with &lt;i>Schistosomia cercariae&lt;/i> through the abdominal skin to induce liver fibrosis. In the intervention group, mice were administered with the respective drugs by gavage after 8 weeks of infection. At the end of</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2025-04-04T22:03:53.375Z</modification><creation>2021-02-21T07:23:04Z</creation></dates><accession>S-EPMC7862569</accession><cross_references><pubmed>33553120</pubmed><doi>10.3389/fbioe.2020.613784</doi></cross_references></HashMap>